

Journal Pre-proof

Urinary VEGF-A165b mRNA expression in Fabry Disease. Pilot study

Sebastián Jaurretche Germán Perez Norberto Antongiovanni María
Victoria del Rosal María Luana Brajkovic Fernando Perretta
Graciela Venera



PII: S0211-6995(25)00126-2

DOI: <https://doi.org/doi:10.1016/j.nefro.2025.501416>

Reference: NEFRO 501416

To appear in: *NEFROLOGÍA*

Received Date: 10 August 2025

Accepted Date: 10 September 2025

Please cite this article as: Jaurretche S, Perez G, Antongiovanni N, Rosal MVd, Brajkovic ML, Perretta F, Venera G, Urinary VEGF-A165b mRNA expression in Fabry Disease. Pilot study (2025), doi: <https://doi.org/10.1016/j.nefro.2025.501416>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.

Urinary VEGF-A165b mRNA expression in Fabry Disease. Pilot study

Sebastián Jaurretche^{1,2}, Germán Perez³, Norberto Antongiovanni⁴, María Victoria del Rosal¹; María Luana Brajkovic¹; Fernando Perretta⁵, Graciela Venera⁶

1. Biophysics and Human Physiology. School of Medicine. Instituto Universitario Italiano de Rosario. (Z.C: 2000) Rosario. Santa Fe. Argentina.
2. Uro-Nephrology and Genetics. Sanatorio Parque. (Z.C: 2000) Rosario. Santa Fe. Argentina.
3. Biochemistry. Nacional University of Rosario. (Z.C: 2000) Rosario. Santa Fe. Argentina.
4. Instituto de Nefrología de Pergamino. (Z.C: 2700) Pergamino. Buenos Aires. Argentina.
5. Hospital Dr. Enrique Erill. (Z.C: 1625) Belén de Escobar. Buenos Aires. Argentina.
6. Research Department. Instituto Universitario Italiano de Rosario. (Z.C: 2000) Rosario. Santa Fe. Argentina.

Correspondence to: Sebastián Jaurretche. Uro-Nephrology and Genetics. Sanatorio Parque. Oroño 860. (Z.C: 2000) Rosario. Santa Fe. Argentina.
Sebastianjaurretche5@gmail.com. ORCID: 000-0002-1462-2703

Abstract

Background: Vascular endothelial growth factor (VEGF) is associated with renal pathogenesis of Fabry disease (FD). Proteomic studies have demonstrated that circulating levels of VEGF are higher in young FD patients compared with controls and an overexpression of tissue VEGF in animal models of Fabry nephropathy has been reported. In kidneys, VEGF-A is predominantly produced by podocytes, and its action on endothelial dysfunction is known. An alternative VEGF-A isoform, VEGF-A165b, confers benefit in microvascular disease states, and it was studied in diabetic nephropathy having demonstrated a protective function, acting on the restoration of the podocyte glycol-calyx.

Methods: cross-sectional design. Urinary mRNA was obtained by RT-qPCR

Results: 48 subjects were included; 24 FD patients (17F/7M - 23.7±17.5 ys) and 24 healthy volunteers (17F/7M - 23.0±17.0 ys). 12 adults and 12 pediatrics in both populations Median uACR (p=0. 999) and eGFR (p=0. 999) were similar between both groups. FD genotypes included were R301Q, R363H, R227Q, del3&4exon, L106R, E398X, L415P and C238Y; 15 FD patients were treatment naïve and 9 receiving ERT

(agalsidase- β); median time of ERT was 15.6 ± 28.3 months. Comparative expression of urinary VEGF-165b-mRNA was higher among FD patients versus controls although without statistical significance ($p=0.369$). No significant correlations were found between urinary VEGF-165b-mRNA and variables “Age” ($p=0.845$), “Gender” ($p=0.369$), “ α Gal-A” ($p=0.631$), “Genotype” ($p=0.142$), “Phenotype” ($p=0.898$), “uACR” ($p=0.744$), “eGFR” ($p=0.059$) and “ERT or Naïve” ($p=0.507$). A significant correlation between urinary VEGF-165b-mRNA and “time of ERT treatment” was found ($p=0.05$).

Conclusion: overexpression of urinary VEGF-165b-mRNA (with known renal cyto-protective effects) is a probable response to injury in FD nephropathy. The only variable correlated with the highest urinary expression of VEGF-165b-mRNA was the time of ERT treatment. Probably in patients with longer treatment time there is a decrease in FD damage. A limitation of the present work is the low sample size and cross-sectional design.

Key words: Urinary VEGF-A165b; mRNA; Fabry disease; nephropathy; biomarkers

Introduction:

Fabry disease (FD; OMIM 301500) is a chronic, progressive and multisystemic lysosomal storage disease [1]. In FD, X-linked genetic variants of GLA gene cause alpha-galactosidase-A (α Gal-A) activity deficiency and, as consequence, glycosphingolipid substrates, mainly globotriaosylceramide (Gb3) accumulates in lysosomes, all cells and tissues throughout the body, leading to organ dysfunction [1]. Globotriaosylsphingosine (Lyso-Gb3), a deacylated molecule from Gb3, circulates in plasma and is capable of causing damage to multiple tissues in affected patients [2].

Life expectancy among FD patients is shorter than the general population due to premature onset of renal disease, cardiomyopathy, malignant arrhythmias, and cerebrovascular events at an early age in both genders [1].

FD renal damage is manifested by pathological albuminuria on childhood and subsequent estimated glomerular filtration rate (eGFR) decrease on adulthood [2]; end-stage kidney disease (ESRD) with requirement of dialysis or transplant occurs at age 40 in males with “classic” FD phenotype (or FD type 1) [2,3]. In women with “classic” FD, renal disease is more variable, usually onset later [2]; while in patients of both genders with the “late-onset” FD (or FD type 2), nephropathy may be the only manifestation or be absent [2].

Pathological albuminuria is then the first clinical manifestation of FD nephropathy [2,3] but some pathophysiological mechanisms are pre-albuminurics [4,5,6]. Then, determining the mechanisms involved in Fabry nephropathy early stages is useful to: i)

delay progression of nephropathy, ii) increase the probability of therapeutic efficacy, before renal fibrosis and iii) develop new potential specific therapies [2,7].

We previously reported miR-200 and miR-29 in early stages of Fabry nephropathy and the possible role of transforming growth factor- β (TGF- β) in podocyte damage and microRNA regulation in FD [8-11]. While TGF- β effects in FD nephropathy have been described [4,12,13], other growth factors such as vascular endothelial growth factor (VEGF) do not have effects well-known in renal damage due to FD among humans. Existing reports regarding the role of VEGF in animal models of FD nephropathy [14] and VEGF circulating levels in humans FD [15] but the VEGF renal effect and VEGF urinary expression in humans FD have not been described. Then, VEGF was associated with renal pathogenesis of FD and, proteomic studies have demonstrated that circulating VEGF levels are higher in young FD patients compared with controls [15] and an overexpression of tissue VEGF in animal models of Fabry nephropathy has been reported [14].

In kidneys, VEGF-A is predominantly produced by podocytes, and its action on endothelial dysfunction is known. An alternative VEGF-A isoform, VEGF-A165b, confers benefit in microvascular disease states, and it was studied in diabetic nephropathy having demonstrated a protective function, acting on the restoration of the podocyte glycol-calyx [16-18].

In this work, we presented results of a pilot study regarding urinary VEGF-A165b mRNA expression in FD patients versus controls.

Methods:

Cross sectional design.

Subjects.

Inclusion criteria: Patients with FD confirmed diagnosis of any age and gender.

Exclusion criteria: (i) patients with a cause of kidney disease other than FD, (ii) patients who, at the moment of screening presented any clinical condition that potentially alters the results of biomarkers included in the study (diabetes mellitus, autoimmune diseases and systemic pathologies that can affect vascular structures were excluded, but not arterial hypertension because it is an accompanying manifestation of FD), and (iii) patients who fulfilled the inclusion criteria but refused to participate in the study.

Elimination criteria were designed to ensure i) the integrity of the results and ii) the safety of the participants. Pre-existing medical conditions, concurrent treatments, or even being unfit to participate in the study at the discretion of the researchers were exclusion criteria.

In order to increase the internal validity of our study, and to increase the certainty of the effect of the variable "Fabry disease" on the variable "urinary excretion of VEGF-165b-mRNA", a control group was included. Healthy subjects with similar demographic characteristics were included as a control group. In this group, as in the FD patient population, any condition that could modify the variable "urinary excretion of VEGF-165b-mRNA" was excluded.

All study subjects gave their informed written consent, authorizing the publication of their results. Adults signed consent and those of pediatric age agreed, and an adult representative also signed, according to local legislation.

Blood and urine samples were taken first thing in the morning on patients fasting. To classify GLA gene variants, www.omim.org/entry/301500 database was used. The quantification of α GAL-A activity was performed by the fluorometric method; values greater than > 4.0 nmol/h/l, were normal. Plasma and urinary creatinine were determined by electrochemiluminescence (Roche Diagnostics). Albuminuria was determined by a colorimetric method (Roche Diagnostics). The uACR was determined by the ratio albumin (mg)/creatinine (gr). eGFR was estimated by the CKD-EPI equation in adults and Schwartz 2009 equation in pediatric patients [19].

mRNA extraction and RT-qPCR

Total RNA extraction was performed according to the MagNA Pure Compact RNA Isolation Kit protocol, Roche Diagnostics, Switzerland. The integrity of the RNA was confirmed by running on an agarose gel, which was found to be suitable for PCR. RNA purity was confirmed using an IMPLEN 330 relative absorbance ratio 260/280 (Implen,

Germany). Samples with a radius greater than 1.8 were used for PCR. A Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Switzerland) was used for RT. Preparation, protocol, reaction conditions and storage were previously described by us [11]. mRNA quantification was performed with an ABI Step One Plus system (Applied Biosystems, USA). Human β -actin was used as a reference housekeeping gene [11]. A FastStart Universal SYBR Green Master/ROX system (Roche Diagnostics, Switzerland) was used for the q-PCR reaction. The quantification of each mRNA relative expression was performed by the $\Delta\Delta C_t$ method [11].

Statistics analysis

Descriptive statistics: Qualitative variables were expressed as percentages and continuous (quantitative) variables as mean \pm standard deviation. Inferential statistics: parametric or non-parametric tests were used depending on the type of variable to be analyzed. A confidence interval of 95% was used. $p < 0.05$ were considered statistically significant. Data was processed in IBM SPSS Statistics database.

Results:

Forty-eight subjects were included: 24 FD patients (17F/7M - 23.7 ± 17.5 ys) and 24 healthy volunteers (17F/7M - 23.0 ± 17.0 ys). 12 adults and 12 pediatrics in both populations. Median uACR ($p=0.999$) and eGFR ($p=0.999$) were similar between both groups. FD genotypes included were: R301Q, R363H, R227Q, del3&4exon, L106R, E398X, L415P and C238Y; 15 FD patients were treatment naïve and 9 receiving ERT (agalsidase- β); median time of ERT was 15.6 ± 28.3 months (table 1).

Comparative expression of urinary VEGF-165b-mRNA was higher among FD patients versus controls although without statistical significance ($p=0.369$) (Figure 1).

No significant correlations were found between urinary VEGF-165b-mRNA and variables "Age" ($p=0.845$), "Gender" ($p=0.369$), " α Gal-A" ($p=0.631$), "Genotype" ($p=0.142$), "Phenotype" ($p=0.898$), "uACR" ($p=0.744$), "eGFR" ($p=0.059$) and "ERT or Naïve" ($p=0.507$).

A significant correlation between urinary VEGF-165b-mRNA and "time of ERT treatment" was found ($p=0.05$ among Fabry population (Figure 2).

There were no other systemic pathologies other than FD in the clinical history of the study subjects, nor did any new ones appear during the present study.

Discussion:

Progression in chronic kidney diseases (CKD) causes the progressive loss of eGFR and move forward ESRD, which happens approximately 40-42 years in FD men classically affected in our geographic region, similar to others [3,7]. Renal fibrosis is the underlying histological lesion of clinical progression in CKD of any cause [20] and it is also not possible to reverse with any therapeutic intervention [20]. TGF- β is the master molecule involved in renal fibrosis [20,21] and in Fabry nephropathy its effect is known [4,12,13], however VEGF, another growth factor involved in renal physiopathology it has not been well studied in FD nephropathy.

VEGF-A is a group of secreted glycoprotein iso-forms that has been reported as an endogenous protective factor [22], mainly described in diabetes vasculopathy [23]. VEGF-A is predominantly produced by podocytes, and its protective actions on the blood-glomerular barrier are known [24].

While VEGF-A165a (a VEGF-A isoform) can accelerate diabetic nephropathy [25], VEGF-A165b is protective and restores endothelial glycocalyx [18].

As mentioned previously, in FD nephropathy there is no evidence regarding the role of VEGF in humans. In 2007, a proteomic study of Moore et al, reported that circulating VEGF-A levels are high in FD affected patients [15] and in 2012, Lee et al, showed evidence regarding high tissue VEGF expression in FD nephropathy animal models and a direct correlation between VEGF expression and increased extracellular matrix components [14]. These works are the background on the topic of the present study.

Regarding the results obtained in this pilot study, our hypotheses are as follows: i) overexpression of urinary VEGF-165b-mRNA (with known renal cyto-protective effects) is a probable response to injury in FD nephropathy, ii) as the unique variable correlated with the highest urinary expression of VEGF-165b-mRNA was the time of ERT treatment, probably in patients with longer treatment time there is a decrease in FD damage.

A limitation of the present work is the low sample size and cross-sectional design. On the other hand, another main limitation of our work is the use of methods that, although standardized, are not validated for determinations in routine practice. This work is a basic science pilot study that should be followed up longitudinally in the future to be eventually translated into the clinic. In the meantime, our novel results only come from a basic science pilot study.

Conclusion:

Overexpression of urinary VEGF-165b-mRNA (with known renal cyto-protective effects) is a probable response to injury in FD nephropathy. The only variable correlated with the highest urinary expression of VEGF-165b-mRNA was the time of ERT treatment. Probably in patients with longer treatment time there is a decrease in FD damage. A limitation of the present work is the low sample size and cross-sectional design.

DECLARATIONS

Acknowledgments:

Not applicable.

Authors' contributions:

All authors made substantial contributions to each of the following aspects: (1) conception and design of the study, or acquisition of data, analysis and interpretation of data, (2) drafting the article or revising it critically for intellectual content, (3) final approval of the submitted version.

Availability of data and materials:

Data of this work is available and can be consulted at: investigacion@iunir.edu.ar

Financial support and sponsorship:

Not applicable.

Conflicts of interest:

All authors declared that there are not conflicts of interest.

Ethical approval and consent to participate and consent for publication:

Protection of human and animal subjects: The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki). The present study was approved by "Comité de Ética y Bioética del Instituto Universitario Italiano de Rosario" (Res: 23/17). The results of this work are derived from data of the Thesis called "Enfermedad de Fabry. Excreción urinaria de microRNAs relacionados a fibrosis renal". Confidentiality of data: The authors declare that they have followed the protocols of their work center on the publication of patient data. Right to privacy and informed consent: The authors have obtained the written informed consent of the patients or subjects mentioned in the article. This document It is available and can be consulted at: investigacion@iunir.edu.ar.

References:

1. Zarate YA, Hopkin RJ. Fabry's disease. *The Lancet*, 2008;372(9647), 1427-1435. DOI:10.1016/S0140-6736(08)61589-5
2. Jaurretche S, Antongiovanni N, Perretta F. Prevalence of renal damage previous to the diagnosis of Fabry disease in Argentina. *Revista de Nefrología, Diálisis y Trasplante*, 2022;42(3), 215-224. ISSN 0326-3428
3. Jaurretche S, Antongiovanni N, Perretta F. Enfermedad vascular en pacientes varones con enfermedad de Fabry en hemodiálisis: estudio de cohorte retrospectivo en Argentina. *Revista de nefrología, diálisis y trasplante*, 2019;39(2), 101-107. ISSN 0326-3428
4. Rozenfeld PA, de los Angeles Bolla M, Quieto P, Pisani A, Feriozzi S, Neuman P, et al. Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis. *Molecular genetics and metabolism*, 2020;129(2), 132-141. DOI:https://doi.org/10.1016/j.ymgme.2019.10.010
5. Trimarchi H, Canzonieri R, Schiel A, Costales-Collaguazo C, Politei J, Stern A, et al. Increased urinary CD80 excretion and podocyturia in Fabry disease. *Journal of Translational Medicine*, 2016;14, 1-8. DOI: 10.1186/s12967-016-1049-8
6. Najafian B, Svarstad E, Bostad L, Gubler MC, Tøndel C, Whitley C, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. *Kidney international*, 2011;79(6), 663-670. DOI: 10.1038/ki.2010.484
7. Jaurretche S, Antongiovanni N, Perretta F. Fabry nephropathy. Role of nephrologist and clinical variables associated with the diagnosis. *Nefrología*, 2019;39(3), 294-300. DOI: 10.1016/j.nefro.2018.10.017
8. Jaurretche S, Venera G, Antongiovanni N, Perretta F, Perez GR. Urinary excretion of microRNAs in young Fabry disease patients with mild or absent nephropathy. *Open Journal of Nephrology*, 2018;8(3), 71-83. DOI:https://doi.org/10.4236/ojneph.2018.83009
9. Jaurretche S, Perez G, Antongiovanni N, Perretta F, Venera G. Variables associated with a urinary MicroRNAs excretion profile indicative of renal fibrosis in Fabry disease patients. *International Journal of Chronic Diseases*, 2019(1), 4027606. DOI:https://doi.org/10.1155/2019/402
10. Jaurretche S, Venera, G, Antongiovanni N, Perretta F, Pérez G. Urinary excretion profile of microRNAs related to renal fibrosis in Fabry disease patients. A pilot study. *Meta Gene*, 2019;19, 212-218. DOI:https://doi.org/10.1016/j.mgene.2018.12.007

11. Jaurretche S, Venera, G, Antongiovanni N, Perretta F, Pérez G. Possible role of Transforming Growth Factor- β on podocyte injury and microRNAs regulation in early Fabry nephropathy stages. *British Journal of Medical & Health Sciences*, 2020;(2)11,594-601. BJMHS450196. www.jmhsci.org
12. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. *Molecular genetics and metabolism*, 2017;122(3), 19-27. DOI: <https://doi.org/10.1016/j.ymgme.2017.09.004>
13. Rozenfeld P, Feriozzi S, Braun F. The role of tubular cells in the pathogenesis of Fabry nephropathy. *Frontiers in Cardiovascular Medicine*, 2024;11, 1386042. DOI:10.3389/fcvm.2024.1386042
14. Lee MH, Choi EN, Jeon YJ, Jung SC. Possible role of transforming growth factor- β 1 and vascular endothelial growth factor in Fabry disease nephropathy. *International journal of molecular medicine*, 2012;30(6), 1275-1280. DOI:10.3892/ijmm.2012.1139
15. Moore DF, Krokhin OV, Beavis RC, Ries M, Robinson C, Goldin E, et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. *Proceedings of the National Academy of Sciences*, 2007;104(8), 2873-2878. DOI:10.3390/cells12162102
16. Foster RR, Hole R, Anderson K, Satchell SC, Coward RJ, Mathieson PW, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. *American Journal of Physiology-Renal Physiology*, 2003;284(6), F1263-F1273. DOI:10.1152/ajprenal.00276.2002
17. Baelde HJ, Eikmans M, Lappin DWP, Doran PP, Hohenadel D, Brinkkoetter PT, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. *Kidney international*, 2007;71(7), 637-645. DOI: 10.1038/sj.ki.5002101
18. Oltean S, Qiu Y, Ferguson JK, Stevens M, Neal C, Russell A, et al. Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. *Journal of the American Society of Nephrology*, 2015;26(8), 1889-1904. DOI: 10.1681/ASN.2014040350
19. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease: improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3:1-150. DOI: 10.1038/kisup.2012.73
20. Humphreys BD. Mechanisms of renal fibrosis. *Annual review of physiology*, 2018;80(1), 309-326. DOI: 10.1146/annurev-physiol-022516-034227

21. Gu YY, Liu XS, Huang XR, Yu XQ, Lan HY. Diverse role of TGF- β in kidney disease. *Frontiers in cell and developmental biology*, 2020;8, 123. DOI: 10.3389/fcell.2020.00123
22. Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE. Vegfa protects the glomerular microvasculature in diabetes. *Diabetes*, 2012; 61(11) 2958–2966. DOI: 10.2337/db11-1655
23. Rask-Madsen C, King GL. Kidney complications: factors that protect the diabetic vasculature. *Nature medicine*, 2010;16(1), 40-41. DOI: 10.1038/nm0110-40
24. Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, et al. Glomerular structure and function require paracrine, not autocrine, VEGF–VEGFR-2 signaling. *Journal of the American Society of Nephrology*, 2010; 21(10), 1691-1701. DOI: 10.1681/ASN.2010030295
25. Saito D, Maeshima Y, Nasu T, Yamasaki H, Tanabe K, Sugiyama H, et al. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. *American Journal of Physiology-Renal Physiology*, 2011;300(4), F873-F886. DOI: 10.1152/ajprenal.00503.2010.

Figure 1: Comparative expression of urinary VEGF-165b-mRNA among Fabry disease patients versus controls




Figure 2: Correlation between urinary VEGF-165b-mRNA and time of enzyme replacement therapy among Fabry population.




Table 1: patient population with Fabry disease included

Age	Gender	Genotype	α Gal-A	uACR	GFR	VEFG-165b	ERT	ERT months
5	F	E398X	Normal	6	138.1	-0,53	NO	0
27	F	R227Q	Normal	6	118.7	-0,35	NO	0
9	F	L415P	Normal	6	183.3	-0,29	NO	0
7	F	L415P	Normal	20	162.4	-10,92	NO	0
26	F	L415P	Normal	18	163.3	0,16	NO	0
46	F	R301Q	Normal	20	72.8	-0,24	NO	0
12	F	E398X	Normal	3	179.04	0,17	NO	0
16	F	E398X	Normal	4	182.9	-0,82	NO	0
15	F	E398X	Normal	39	139.7	1,8	NO	0
27	F	E398X	Normal	43	111.0	16,29	NO	0
38	F	R363H	Normal	4	115.0	1,23	YES	18
36	F	R227Q	Normal	6	131.9	0,06	YES	24
55	F	R227Q	Normal	14	97.5	0,24	YES	24
38	F	L415P	Normal	63	104.5	-0,58	YES	89
70	F	del3&4exon	Normal	178	63.9	2,12	Yes	39
23	M	L106R	Low	6	104.4	-0,54	NO	0
8	M	E398X	Low	11	174.8	-0,16	NO	0
7	M	E398X	Low	19	159.5	-0,36	NO	0
10	F	L415P	Low	7	166.0	-0,25	NO	0
18	F	L415P	Low	29	151.5	2,06	NO	0
17	M	L415P	Low	135	176.42	-0,51	YES	24
7	M	L415P	Low	3	128.33	-0,4	YES	24
11	M	L415P	Low	8	185.95	-0,66	YES	24

41	M	C238Y	Low	8	84.8	15,59	YES	108
----	---	-------	-----	---	------	-------	-----	-----

References: α Gal-A: α Galactosidase-A; uACR: urinary albumin/creatinine ratio; GFR: glomerular filtration rate; VEGF-165b: vascular endothelial growth factor-165-b; ERT: enzyme replacement therapy; ERT months: months of enzyme replacement therapy.

Journal Pre-proof



Dear Editor:

Journal: " Revista Nefrología "

In this letter I request the evaluation of the manuscript " Urinary VEGF-A165b mRNA expression in Fabry Disease. Pilot study " for the "original breve" section of your prestigious journal.

It is an original work, that it has not been previously submitted to or accepted by any other journal, that is has been approved by all authors.

None of the authors have any conflicts of interest with the contents of the manuscript.

Kind regards.



Prof. Dr. Sebastián P. A. Jaurretche

Sanatorio Parque SA

Journal